NCT02741544View on ClinicalTrials.gov

Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])

CompletedOBSERVATIONAL
Enrollment

578

Participants

Timeline

Start Date

March 3, 2016

Primary Completion Date

August 20, 2020

Study Completion Date

August 20, 2020

Conditions
Multiple Myeloma
Trial Locations (1)

651-0072

Shinko Hospital, Kobe

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT02741544 - Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM]) | Biotech Hunter | Biotech Hunter